John Herrmann to Speak at 3rd Oncology Partnering & Deal-Making Conf - July 7-8, 2014 in Boston

Boston, MA, April 27, 2014 --(PR.com)-- John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the 3rd Oncology Partnering & Deal-Making Conference to be held on July 7-8, 2014 in Boston, MA.

This presentation will outline what sorts of assets & platforms that Lilly Oncology is currently prioritizing while also providing a glimpse of our internal process for assessing a biotech’s innovation for fit with Lilly’s portfolio and long-range strategy. Alternative ways of partnering with Lilly including their capital funds channel, the NYC Innovation Hub model and their Open Innovation Drug Discovery (OIDD) will also be highlighted. Lastly, this presentation will take a look into a future (10+ years away) of potentially-disruptive technologies that may create future states with weighty implications to our bio/pharma business models and the oncology partnering ecosystem.

John Herrmann is the Chief Science Officer, Global External R&D-Oncology. He is responsible for systematically prioritizing & risk assessing the external ecosystem of oncology innovations spanning academia, biotechs and peer pharmas in support of the strategy and growth needs of Lilly Oncology.

GTCBio's 3rd Oncology Partnering & Deal-Making Conference is a partnership and business development conference that provides an opportunity for attendees to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as giving them an opportunity to explore potential collaborations and learn about relevant issues in oncology that will affect the industry. Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, partnership opportunities, alliance management, value maximization vs. capital efficiency, and IPOs. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum.

This conference is part of the larger Novel Cancer Therapeutics Summit, which consist of two co-located parallel conferences:

3rd Oncology Partnering & Deal-making Conference
5th Cancer Targets & Therapeutics Conference

For more information, please visit www.gtcbio.com